Navigation Links
Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
Date:11/7/2011

t had expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide licenses for technology and intellectual property for novel DNA vaccines against prostate cancer, CMV (cytomegalovirus), malaria, hepatitis B, RSV (respiratory syncytial virus), and MRSA (methicillin-resistant staphylococcus aureus) as well as a new optimized IL-12 cytokine gene adjuvant.

Inovio entered into a Cooperative Research and Development Agreement with the United States Department of Homeland Security Science and Technology Directorate Plum Island Animal Disease Center to evaluate the efficacy of its synthetic vaccines for foot & mouth disease in animal models.

Inovio also established a product development agreement with its affiliate, VGX International Inc., to co-develop Inovio's SynCon® therapeutic vaccines for hepatitis B and C infections.

The company expanded its scientific advisory board with the appointment of two prominent leaders in the fields of vaccines and cancer immunotherapeutics: Dr. Thomas S. Edgington, Emeritus Professor of the Scripps Research Institute; and Dr. Philip D. Greenberg, Professor of Medicine (Oncology) and Immunology, Department of Medicine, University of Washington.

Clinical DevelopmentLong-term durability of T cell immune responses of up to two years (at the latest time measured) was observed following a fourth (Phase I) vaccination of VGX-3100, Inovio's SynCon® DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus. The company continues to set up sites and enroll patients for its Phase II clinical trial assessing the vaccine in women with CIN 2/3 or CIN 3 cervical dysplasias, the stages of abnormal cells preceding cervical cancer. The company expects to enroll 148 patients in 25 study centers in the U.S., South Korea, South Africa, Australia, and Canada. Data is expected in the second half of 2013.

Significant T
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance for ... fatigue. The need to urgently address this issue ... Sentinel Event Alert #50 , "Medical device alarm safety in ... between January 2008 and June 2012, there were 98 alarm ... in death (82%) , 13 resulted in permanent loss ...
(Date:6/19/2013)... June 19, 2013   Voices Against Brain Cancer ... cure for brain cancer, today announced that it has ... support the clinical investigation of Toca 511 & Toca ... glioma brain cancer (Grade 3 or Grade 4).  Tocagen ... for advanced cancer, with an initial focus on brain ...
(Date:6/19/2013)... 2013   Nektar Therapeutics (Nasdaq: NKTR ... liability (HAL) study for NKTR-181, a first-in-class, opioid ... brain.  This slow rate of entry is designed to reduce ... addiction to current opioid analgesics. 1 In the study ... to placebo in "drug liking" and "feeling high" scores and ...
Breaking Medicine Technology:Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9
... JUNCTION, N.J., Nov. 14, 2011 Insmed Incorporated (Nasdaq CM: ... and CEO of Insmed, will be presenting a corporate overview ... Wednesday, November 16, 2011, at 8:30 AM ET, in New ... available on Insmed,s website, http://www.insmed.com .  The webcast will ...
... N.J., Nov. 14, 2011 Soligenix, Inc. (OTCBB: SNGX) ... announced today its financial results for the third quarter ... third quarter of 2011 were approximately $5,796,000 as compared ... increase in revenues was a result of a $5 ...
Cached Medicine Technology:Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference 2Soligenix Reports Third Quarter 2011 Financial Results 2Soligenix Reports Third Quarter 2011 Financial Results 3Soligenix Reports Third Quarter 2011 Financial Results 4Soligenix Reports Third Quarter 2011 Financial Results 5
(Date:6/19/2013)... (PRWEB) June 19, 2013 Strict ... In July 2013, Orriant is launching a new ... and maintain compliance with regulations. New HHS ... receive wellness incentives if their employer offers outcome-based, ... have been compliant with these standards for nearly ...
(Date:6/19/2013)... June 19, 2013 As Januvia ... continue to mount in courts throughout the U.S., Bernstein ... Administration (FDA) recently held a meeting to discuss the ... incretin mimetics. According to a June 12th report ... the makers of Januvia and similar drugs, following a ...
(Date:6/19/2013)... In what is believed to be the largest ... of hereditary dystonia a movement disorder that can ... stimulation report good success rates and lasting benefits. , ... Program at Cedars-Sinai Medical Center,s Department of Neurology, and ... Neurosurgery at Beth Israel Deaconess Medical Center in Boston, ...
(Date:6/19/2013)... of Iowa study reveals significant disparities between minority ... substance abuse treatment programs. Moreover, these disparities vary ... findings suggest that for most states there,s something ... psychiatry and biostatistics. "There are strong racial and ... complete substance abuse treatment programs successfully, and those ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 ... of neurologists, neurosurgeons, psychiatrists and urologists with specialists ... The team works with patients and their family ... overall quality of life. Patients also have the ... trials and research. , “Movement disorders can be ...
Breaking Medicine News(10 mins):Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2
... a knotty affair for most young adults in the UK ... them cannot solve basic maths questions meant for 8-year-olds, according ... conducted to mark the release of the ITV DVD Numberjacks: ... brain gain software props up pre-school children to learn key ...
... lower the rapidly rising costs of several anticancer drugs, ... suggest in a commentary in the Journal of Clinical ... MD, and Ezra Cohen, MD, call attention to the ... can alter absorption or delay breakdown of precisely targeted ...
... high caloric load of sugars, appears to be a healthy ... a study by endocrinologists at the University at Buffalo ... 2007 issue of Diabetes Care. ,Flavonoids suppress destructive ... or ROS. An overabundance of free radicals can,damage all components ...
... India is seeking consular access to Mohammed Haneef, currently ... bombing. ,On Tuesday the Indian External Affairs ... express its concern over the treatment of Haneef. ... to the Australian Government that Dr Mohamed Haneef should ...
... Neurology, the medical journal of the American Academy of Neurology,Older ... cognitive decline to have problems falling asleep and staying ... average age of 69 and no signs of memory problems ... at the end of the study. ,The study ...
... parties seek to position themselves as great champions of ... Tim Flannery, the Australian of the Year Professor who ... opposition to come out with specific proposals instead of ... has also faulted the John Howard government's move to ...
Cached Medicine News:Health News:Value Meal Would Lower Drug Costs 2Health News:Value Meal Would Lower Drug Costs 3Health News:Flavonoids In Orange Juice Make It A Healthy Drink, Despite The Sugar 2Health News:Memory Problem in Older Women Lead to Restless Nights 2Health News:Subsidize Solar Water Heaters for Homes, Expert Tells Australian Government 2
... dryer is an electrophoresis gel vacuum dryer that ... dries these gels onto cellophane or filter paper ... elements which heat gels from above. The drying ... V unit includes power cord, porous gel support, ...
... a constant voltage power supply, the 105 is ... hilo range switch control the output, which is ... volts. One, two-position switch toggles the bright LED ... The 105 is equipped with an over current ...
... From simple techniques such as submarine electrophoresis ... Step IEF, the Series 90 Programmable Power ... Series 90 Programmable Power Supplies are available ... or 6000V., All models operate in constant ...
MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...
Medicine Products: